{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T15:14:32Z","timestamp":1767453272315,"version":"3.41.2"},"reference-count":31,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":206,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["IndiGen (2019)"],"award-info":[{"award-number":["IndiGen (2019)"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The steady increase in global cancer burden has fuelled the development of several modes of treatment for the disease. In the presence of an actionable mutation, targeted therapies offer a method to selectively attack cancer cells, increasing overall efficacy and reducing harmful side effects. However, different drug molecules are in different stages of development, with new molecules obtaining approvals from regulatory agencies each year. To augment clinical impact, it is important that this information reaches clinicians, patients and researchers swiftly and in a structured, well-annotated manner. To this end, we have developed Mutation-Specific Therapies Resource and Database in Cancer (MUSTARD), a database that is designed to be a centralized resource with diverse information such as cancer subtype, associated mutations, therapy offered and its effect observed, along with links to external resources for a more comprehensive annotation. In its current version, MUSTARD comprises over 2105 unique entries, including associations between 418 unique drug therapies, 189 cancer subtypes and 167 genes curated and annotated from over 862 different publications. To the best of our knowledge, it is the only resource that offers comprehensive information on mutation-specific, gene fusions and overexpressed gene-targeted therapies for cancer.<\/jats:p>\n               <jats:p>Database URL: http:\/\/clingen.igib.res.in\/mustard\/<\/jats:p>","DOI":"10.1093\/database\/baab042","type":"journal-article","created":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T11:08:13Z","timestamp":1624878493000},"source":"Crossref","is-referenced-by-count":3,"title":["MUSTARD\u2014a comprehensive resource of mutation-specific therapies in cancer"],"prefix":"10.1093","volume":"2021","author":[{"given":"Gauri","family":"Mittal","sequence":"first","affiliation":[{"name":"Indraprastha Institute of Information Technology, Okhla Industrial Estate, Phase III, Delhi 110020, India"}]},{"given":"Anu","family":"R I","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, MVR Cancer Center and Research Institute, CP 13\/516 B, C, Vellalasseri NIT(Via), Poolacode, Kozhikode 673601, India"},{"name":"Cancer Biology and Therapeutics: High-Impact Cancer Research Post Graduate Program, Harvard Medical School, 4 Blackfan Circle, Boston, MA 02115, USA"}]},{"given":"Aastha","family":"Vatsyayan","sequence":"additional","affiliation":[{"name":"Department of Genome Informatics, CSIR Institute of Genomics and Integrative Biology (CSIR-IGIB), Mathura Road, Delhi 110025, India"},{"name":"Academy of Scientific and Innovative Research (AcSIR), Sector 19, Kamla Nehru Nagar, Ghaziabad, UP 201002, India"}]},{"given":"Kavita","family":"Pandhare","sequence":"additional","affiliation":[{"name":"Department of Genome Informatics, CSIR Institute of Genomics and Integrative Biology (CSIR-IGIB), Mathura Road, Delhi 110025, India"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7644-7181","authenticated-orcid":false,"given":"Vinod","family":"Scaria","sequence":"additional","affiliation":[{"name":"Department of Genome Informatics, CSIR Institute of Genomics and Integrative Biology (CSIR-IGIB), Mathura Road, Delhi 110025, India"},{"name":"Academy of Scientific and Innovative Research (AcSIR), Sector 19, Kamla Nehru Nagar, Ghaziabad, UP 201002, India"}]}],"member":"286","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"key":"2021072612220010500_R1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"2021072612220010500_R2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1570163812666150602144310","article-title":"Targeted cancer therapy: the next generation of cancer treatment","volume":"12","author":"Baudino","year":"2015","journal-title":"Curr. Drug Discov. Technol."},{"key":"2021072612220010500_R3","doi-asserted-by":"crossref","DOI":"10.7603\/s40681-015-0019-4","article-title":"An overview of targeted cancer therapy","volume":"5","author":"Padma","year":"2015","journal-title":"Biomedicine"},{"key":"2021072612220010500_R4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00263","article-title":"Identification of genetic mutations in cancer: challenge and opportunity in the new era of targeted therapy","volume":"9","author":"Jin","year":"2019","journal-title":"Front. Oncol."},{"key":"2021072612220010500_R5","doi-asserted-by":"crossref","DOI":"10.4103\/0976-9668.184695","article-title":"Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation. Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation","volume":"7","author":"Nurwidya","year":"2016","journal-title":"J. Nat. Sci. Biol. Med."},{"year":"2020","author":"Office of the Commissioner","key":"2021072612220010500_R6"},{"key":"2021072612220010500_R7","article-title":"Drug approved for rare mutation in gastrointestinal tumor","volume":"323","author":"Voelker","year":"2020","journal-title":"JAMA"},{"key":"2021072612220010500_R8","doi-asserted-by":"crossref","DOI":"10.1186\/s40246-016-0061-7","article-title":"The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies","volume":"10","author":"Patterson","year":"2016","journal-title":"Hum. Genomics"},{"key":"2021072612220010500_R9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2017.00214","article-title":"Resources for interpreting variants in precision genomic oncology applications","volume":"7","author":"Tsang","year":"2017","journal-title":"Front. Oncol."},{"key":"2021072612220010500_R10","doi-asserted-by":"crossref","DOI":"10.1038\/ng.3774","article-title":"CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer","volume":"49","author":"Griffith","year":"2017","journal-title":"Nat. Genet."},{"key":"2021072612220010500_R11","article-title":"OncoKB: a precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"2021072612220010500_R12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jamia\/ocw148","article-title":"The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations","volume":"24","author":"Huang","year":"2017","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"2021072612220010500_R13","first-page":"A68","article-title":"The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge","volume":"19","author":"Tomczak","year":"2015","journal-title":"Contemp. Oncol."},{"key":"2021072612220010500_R14","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal"},{"key":"2021072612220010500_R15","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","article-title":"Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"key":"2021072612220010500_R16","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","article-title":"Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing","volume":"36","author":"Rizvi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"2021072612220010500_R17","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the evolution of non-small-cell lung cancer","volume":"376","author":"Jamal-Hanjani","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"2021072612220010500_R18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.lungcan.2016.05.021","article-title":"Precision medicine in age-specific non-small-cell-lung-cancer patients: integrating biomolecular results into clinical practice-a new approach to improve personalized translational research","volume":"107","author":"Vaval\u00e0","year":"2017","journal-title":"Lung Cancer"},{"key":"2021072612220010500_R19","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.3564","article-title":"Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas","volume":"48","author":"Campbell","year":"2016","journal-title":"Nat. Genet."},{"key":"2021072612220010500_R20","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"2021072612220010500_R21","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1158\/2159-8290.CD-16-1337","article-title":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","volume":"7","author":"Jordan","year":"2017","journal-title":"Cancer Discov."},{"key":"2021072612220010500_R22","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cell.2012.08.029","article-title":"Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing","volume":"150","author":"Imielinski","year":"2012","journal-title":"Cell"},{"key":"2021072612220010500_R23","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature07423","article-title":"Somatic mutations affect key pathways in lung adenocarcinoma","volume":"455","author":"Ding","year":"2008","journal-title":"Nature"},{"key":"2021072612220010500_R24","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkt1113","article-title":"ClinVar: public archive of relationships among sequence variation and human phenotype","volume":"42","author":"Landrum","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"2021072612220010500_R25","doi-asserted-by":"crossref","first-page":"D1068","DOI":"10.1093\/nar\/gkx1143","article-title":"DGIdb 3.0: a redesign and expansion of the drug\u2013gene interaction database","volume":"46","author":"Cotto","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"2021072612220010500_R26"},{"key":"2021072612220010500_R27","doi-asserted-by":"crossref","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"2021072612220010500_R28","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2019.10.23","article-title":"CMTTdb: the cancer molecular targeted therapy database","volume":"7","author":"Bai","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"2021072612220010500_R29","first-page":"D1031","article-title":"Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics","volume":"48","author":"Wang","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"2021072612220010500_R30","doi-asserted-by":"crossref","first-page":"D668","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: a comprehensive resource for in silico drug discovery and exploration","volume":"34","author":"Wishart","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"2021072612220010500_R31","doi-asserted-by":"crossref","first-page":"D1054","DOI":"10.1093\/nar\/gkv1037","article-title":"The IUPHAR\/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands","volume":"44","author":"Southan","year":"2016","journal-title":"Nucleic Acids Res."}],"container-title":["Database"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/database\/article-pdf\/doi\/10.1093\/database\/baab042\/39313822\/baab042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/database\/article-pdf\/doi\/10.1093\/database\/baab042\/39313822\/baab042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T12:22:26Z","timestamp":1627302146000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/database\/article\/doi\/10.1093\/database\/baab042\/6328507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":31,"URL":"https:\/\/doi.org\/10.1093\/database\/baab042","relation":{},"ISSN":["1758-0463"],"issn-type":[{"type":"electronic","value":"1758-0463"}],"subject":[],"published-other":{"date-parts":[[2021,1,1]]},"published":{"date-parts":[[2021,1,1]]},"article-number":"baab042"}}